SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs zooms on getting product permission from CDSCO for Tofacitinib Ointment

10 Oct 2023 Evaluate

Lyka Labs is currently trading at Rs. 123.00, up by 4.70 points or 3.97% from its previous closing of Rs. 118.30 on the BSE.

The scrip opened at Rs. 116.25 and has touched a high and low of Rs. 125.75 and Rs. 116.25 respectively. So far 14701 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 155.65 on 19-Jan-2023 and a 52 week low of Rs. 89.00 on 25-May-2023.

Last one week high and low of the scrip stood at Rs. 127.90 and Rs. 115.90 respectively. The current market cap of the company is Rs. 410.32 crore.

The promoters holding in the company stood at 54.58%, while Institutions and Non-Institutions held 0.58% and 44.85% respectively.

Lyka Labs has received the product permission from the Central Drugs Standard Control Organization of India (CDSCO) to Manufacture and Market Tofacitinib Ointment 2% w/w. The company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India. 

Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.


Lyka Labs Share Price

65.10 3.10 (5.00%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×